CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
AFP, AFP-L3% and DCP levels in patients with advanced hepatocellular carcinoma treated with sorafenib
DOI 10.1055/s-0029-1191987
Bibliografische Angaben
Nachweis in CareLit
Autor:innenH Schulze-Bergkamen, A Weinmann, M Wörns, PR Spies, A Teufel, C Düber, G Otto, A Shresta, B Vick, R Küper, J Schurek, PR Galle, M Schuchmann, M Volkmann
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe01/2009
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: Patients suffering from advanced hepatocellular carcinoma (HCC) have a dismal prognosis with survival rates of less than six months. The multikinase inhibitor sorafenib (Nexavar®) was recently approved for the treatment of advanced HCC providing survival benefit (Llovet, NEJM, 2008). Considering the shortcomings of RECIST criteria in the age of targeted therapy we have investigated serum levels of alpha-…
Zitieren
Zitierempfehlung
H Schulze-Bergkamen, A Weinmann, M Wörns, PR Spies, A Teufel, C Düber, G Otto, A Shresta, B Vick, R Küper, J Schurek, PR Galle, M Schuchmann, M Volkmann (2009) AFP, AFP-L3% and DCP levels in patients with advanced hepatocellular carcinoma treated with sorafenib. Zeitschrift für Gastroenterologie (01). https://doi.org/10.1055/s-0029-1191987
Mit CareLit weiterarbeiten